Success Metrics

Clinical Success Rate

80.0%

Based on 4 completed trials

Completion Rate

80%(4/5)

Active Trials

0(0%)

Results Posted

50%(2 trials)

Terminated

1(14%)

Phase Distribution

Ph phase_1

57%

Ph phase_2

43%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution7 total trials

Phase 1Safety & dosage

4(57.1%)

Phase 2Efficacy & side effects

3(42.9%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(4)

Terminated(1)

Other(1)

Detailed Status

Completed4

unknown1

Not yet recruiting1

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

80.0%

Most Advanced

Phase 2

Trials by Phase

Phase 14 (57.1%)

Phase 23 (42.9%)

Trials by Status

unknown114%

not_yet_recruiting114%

terminated114%

completed457%

Recent Activity

0 active trials

Showing 5 of 7

not_yet_recruitingphase_2

Inhibition of Aggressive Behavior in Participants With Fragile X Syndrome

NCT07328529

completedphase_1

Safety, Tolerability and Activity of SRX246 in Adults With Intermittent Explosive Disorder

NCT02055638

completedphase_2

Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease

NCT02507284

terminatedphase_2

Proof-of-concept Study to Assess the Efficacy and Safety of SRX246 in Adults With PTSD

NCT02733614

unknownphase_1

Effects of SRX246 on an Experimental Model of Fear and Anxiety in Humans

NCT02922166

View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials

NCT07328529Phase 2

Inhibition of Aggressive Behavior in Participants With Fragile X Syndrome

Not Yet Recruiting

NCT02055638Phase 1

Safety, Tolerability and Activity of SRX246 in Adults With Intermittent Explosive Disorder

Completed

NCT02507284Phase 2

Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease

Completed

NCT02733614Phase 2

Proof-of-concept Study to Assess the Efficacy and Safety of SRX246 in Adults With PTSD

Terminated

NCT02922166Phase 1

Effects of SRX246 on an Experimental Model of Fear and Anxiety in Humans

Unknown

NCT01088932Phase 1

Multiple Dose Safety Study of SRX246 Capsules in Healthy Volunteers

Completed

NCT00910455Phase 1

Study of SRX246 Capsules in Healthy Adult Volunteers

Completed

All 7 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 7